Cetera Investment Advisers Purchases 5,624 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Cetera Investment Advisers increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 32.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,173 shares of the biopharmaceutical company’s stock after acquiring an additional 5,624 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $7,667,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $243,000. Geneos Wealth Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 175 shares in the last quarter. Flow Traders U.S. LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $241,000. Daiwa Securities Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after purchasing an additional 35 shares during the last quarter. Finally, NewEdge Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 70,300.0% in the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 703 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Royal Bank Of Canada dropped their price objective on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday. Stifel Nicolaus decreased their target price on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a research report on Friday. HC Wainwright reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Friday. Needham & Company LLC dropped their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a report on Thursday. Finally, Truist Financial dropped their target price on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $410.72.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Chardan Capital reaffirmed its Buy rating and assigned a $425 price target, while JPMorgan, RBC, Oppenheimer, and Stifel maintained bullish ratings despite lowering their targets. The revised targets remain well above the current trading level. Analyst ratings and price targets
• Positive Sentiment: Alnylam reported continued strength in its transthyretin franchise, including record quarterly Amvuttra sales, and revenue increased substantially from the prior-year period. These results support the company’s underlying commercial momentum. Alnylam Q2 2026 earnings call
• Neutral Sentiment: Analysts broadly lowered their targets: JPMorgan cut its target to $375, RBC to $350, Oppenheimer to $350, Stifel to $318, Wells Fargo to $316, and Morgan Stanley to $300. Ratings range from Buy/Outperform to Equal Weight, indicating optimism about valuation but greater near-term uncertainty. Analyst price-target changes
• Negative Sentiment: Second-quarter adjusted earnings of $1.84 per share exceeded some consensus measures but missed the $2.05 Zacks estimate, while revenue of $1.29 billion fell short of the roughly $1.32 billion consensus. Alnylam Q2 earnings miss
• Negative Sentiment: The company cut its 2026 product-revenue outlook to $5.3 billion-$5.7 billion, reflecting normalization in second-line Amvuttra demand and headwinds affecting the ATTR-CM market. The guidance reduction is the primary catalyst behind the stock’s decline. Alnylam lowers 2026 outlook
• Negative Sentiment: Several law firms announced securities-fraud investigations following the results and guidance cut. These announcements may add reputational and legal overhang, although they do not establish wrongdoing. Securities-fraud investigation

Alnylam Pharmaceuticals Trading Up 0.0%

ALNY opened at $205.52 on Friday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The firm has a market capitalization of $27.44 billion, a price-to-earnings ratio of 38.20 and a beta of 0.27. The company’s 50 day moving average price is $287.96 and its two-hundred day moving average price is $311.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 104.81%. The company’s revenue was up 96.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.44) EPS. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.22 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.